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Urinary Tract Infection (UTI) Clinical Practice Guideline (CPG)

Diagnosing Urinary Tract Infections (UTIs)

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Managing UTI/Pyelonephritis (Inpatient & Outpatient)

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Renal Imaging for UTI/Pyelonephritis

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Guideline Objective

To provide care standards for the otherwise healthy patient 2 months of age or greater with suspected or
confirmed first-time or recurrent urinary tract infection (UTI). This guideline was developed to assist clinicians in
ambulatory and inpatient settings with the diagnosis, management, and follow-up of patients with UTI or
pyelonephritis.

Epidemiology

UTIs are common within the pediatric population and account for nearly 1% of office visits and 5 to 14% of
pediatric Emergency Department (ED) visits (Shaikh et al., 2008). Age, toilet training status, sex, comorbidities
affecting bowel or bladder function (such as spina bifida, congenital anomalies of the kidney, constipation), and in
older children, diabetes, kidney stones, and sexual activity, are all risk factors for UTI.

In the first year of life, UTI is more common in boys (3.7%) compared to 2% in girls (Mattoo et al., 2021).
However, after infancy UTI is significantly more prevalent in girls. UTIs are typically caused from colonic bacteria
creating infection/inflammation which ascends from the urethra into the bladder. If the inflammatory process is
localized to the bladder (cystitis), it is considered a lower UTI; while an upper UTI occurs if inflammation ascends
to the ureters and kidneys (pyelonephritis). In otherwise healthy children, the majority (85% to 90%) of UTIs are
caused by Escherichia coli, while infections with Klebsiella, Proteus (more common with stone formation),
Enterococcus, and Enterobacter species are less common (Mattoo et al.). Atypical organisms, including
Pseudomonas spp, group B Streptococcus, Staphylococcus aureus, are usually associated with congenital kidney
anomalies, genitourinary surgery, or foreign body (such as a catheter) (Mattoo et al.).

Target Users
•

•
•

Physicians (Ambulatory, Urgent Care, Emergency Department, Hospitalist, Community Physicians, Fellows,
and Resident Physicians)
Advanced Practice Providers
Nurses

Target Population

Guideline Inclusion Criteria
•
> 60 days of age
•
Healthy child with possible or confirmed first-time or recurrent UTI
Guideline Exclusion Criteria
•
Chronic Kidney Disease
•
Suspected or known genitourinary abnormalities, such as (but not limited to): previous genitourinary
surgery (other than circumcision), neurogenic bladder or bowel conditions, obstructive uropathy,
vesicoureteral reflux
•
Septic shock
•
Presumed or definite meningitis
•
Immunocompromised host
•
Pregnancy
•
Concern for sexual abuse

AGREE

The American Academy of Pediatrics national guideline (Subcommittee On Urinary Tract Infection, 2016) and the
National Institute for Health and Care Excellence (2018) international guideline provided guidance to the CM
UTI CPG committee. See Table 1 and 2 for the AGREE II summaries associated with these guidelines.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Table 1
AGREE IIa Summary for the Subcommittee On Urinary Tract Infection (2016)
Percent Justification
Domain
Percent Agreement
The aim of the guideline, the clinical questions posed
and target populations were identified.
The guideline was developed by the appropriate
Stakeholder involvement
58%
stakeholders. However, it did not include the patient’s
perspective
A full description of research methodology was provided
in the 2011 guideline. A list of new references is
provided with the 2016 reaffirmation. The methodology
Rigor of development
67%
regarding the level of evidence assessment was not
provided. No changes were made to the evidence
quality for the individual action statements.
The guideline recommendations are clear,
Clarity and presentation
74%
unambiguous, and easily identified; in addition,
different management options are presented.
Barriers and facilitators to implementation, and
strategies to improve utilization were discussed but
Applicability
70%
not clearly addressed in the guideline. The guideline
did provide monitoring criteria.
The recommendations were not biased with competing
Editorial independence
100%
interests.
Modifications to this guideline include antibiotics based
Committee’s
on Children’s Mercy (CM) Hospital antibiogram data and
recommendation for
Yes, with modifications
literature related to the use of leukocyte esterase (LE)
guideline use
and nitrite testing.
Note: Four EBP Scholars completed the AGREE II on this guideline.
Scope and purpose

81%

Table 2
AGREE IIa Summary for the National Institute for Health and Care Excellence (NICE) (2018)
Percent Justification
Domain
Percent Agreement
The aim of the guideline, the clinical questions posed
and target populations were identified.
The guideline was developed by the appropriate
Stakeholder
83%
stakeholders and represents the views of its intended
involvement
users.
The process used to gather and synthesize the
evidence, the methods to formulate the
Rigor of development
73%
recommendations and to update the guidelines were
explicitly stated.
The guideline recommendations are clear,
Clarity and presentation
86%
unambiguous, and easily identified; in addition,
different management options are presented.
Barriers and facilitators to implementation, strategies to
Applicability
90%
improve utilization and resource implications were
addressed in the guideline.
It is unclear if the recommendations were biased by
competing interests as the authors did not address how
Editorial independence
6%
conflicts of interest were assessed or managed nor who
funded the guideline development.
Committee’s
Modifications to this guideline include antibiotics based
recommendation for
Yes with modifications
on CM Hospital antibiogram data and literature related
guideline use
to the use of LE and nitrite testing.
Note: Four EBP Scholars completed the AGREE II on this guideline.
Scope and purpose

96%

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.

Date Finalized: 05/24/22
7

Additional Questions Posed by the CPG Committee

Is Kirby Bauer testing indicated to determine if the Enterobacter species is susceptible to cefazolin?
Recommendations from the UTI Clinical Practice Guideline (CPG) Committee
In January 2010, the Clinical and Laboratory Standards Institute (CLSI) published new minimum inhibitory
concentration (MIC) breakpoints for cefazolin against Enterobacteriaceae (Wayne, 2010). These new
breakpoints were largely based on data from bloodstream infections in adults and do not necessarily
reflect increased intrinsic resistance of E.coli to cefazolin.
A Kirby Bauer (KB) disk diffusion test can be helpful to identify isolate susceptibility to cefazolin or
cephalexin based on these new MIC breakpoints. However, utilizing a higher dose of cefazolin (i.e. 100 –
150 mg/kg/day) or cephalexin (i.e. 75 – 100 mg/kg/day) is likely to overcome intermediate susceptibility
for Enterobacteriaceae (e.g E. coli, Klebsiella pneumoniae, Proteus mirabilis) in urinary tract infections,
including uncomplicated pyelonephritis.
Therefore, the CMH Urinary Tract Infection Clinical Practice Guideline Committee and subject matter
experts recommend higher dose cefazolin or cephalexin without the need for KB disk diffusion in most
cases. KB disk diffusion is still recommended for patients who do not respond appropriately to empiric
treatment with cefazolin/cephalexin or who are excluded from this guideline (e.g., urologic abnormalities,
kidney disease/injury, septic shock, or immunocompromised).
In patients > 2 months of age with signs or symptoms of UTI, what is the Positive Predictive Value (PPV) for
leukocyte esterase (LE) or nitrites (alone or in combination) to diagnose a UTI compared to the gold standard of a
positive urine culture?
Recommendations from the UTI CPG Committee
•
A conditional recommendation is made for obtaining a urine culture and treating empirically for a UTI
if nitrites are positive, based on the GRADE Summary of Findings Tablea (see page 9). The
recommendation is based on a very low level of evidence (see Summary by Outcome for
substantiation of recommendations). The overall PPV for nitrites to diagnose a UTI was 84% with a
negative predictive value (NPV) of 89%.
•
A strong recommendation is made for obtaining a urine culture and treating empirically for UTI if
nitrites and LE are positive, based on the GRADE Summary of Findings Tablea (see page 10). The
recommendation is based on a moderate level of evidence (see Summary by Outcome for
substantiation of recommendations). The overall PPV for LE and nitrites to diagnose a UTI was 93%
with a NPV of 94%.
•
No literature was found that tested the use of LE alone to accurately identify the need to obtain a
urine culture and treat empirically for a UTI within the last five years.

Children’s Mercy Practice Recommendations and Reasoning

Children’s Mercy adopted a majority of the practice recommendations made by the AAP Clinical Practice Guideline
(Subcommittee On Urinary Tract Infection, 2016) and the NICE guideline (2018). However, as a diagnosis is
typically made with a combination of clinical signs and symptoms along with abnormal urinalysis, then later
confirmed by urine culture, the urinalysis must be correctly obtained and interpreted. Diagnosis is essential to
mitigate the acute risks associated with UTI or pyelonephritis, including renal abscess, acute kidney injury, and
urosepsis. It is also key in decreasing long-term risks of renal scarring and chronic kidney disease. Hence, the
recommendation to obtain a urine culture and treat empirically for UTI if nitrites and LE are positive.

Historically, empiric treatment consisted of a broad-spectrum antibiotic, usually a third-generation cephalosporin.
More recent evidence suggests the use of an antibiotic with a narrower spectrum, such as first-generation
cephalosporin, is as effective (Daley et al., 2020; Poole et al., 2020). While treatment duration of 7 to 14 days
was previously recommended (Roberts, 2011), shorter durations are often appropriate. Shorter duration of
narrower agents may decrease the risk of adverse medication effects and antimicrobial resistance while also
decreasing healthcare costs (Fox et al., 2020).

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Measures

Outcome:
•
Proportion of encounters meeting inclusion and diagnosed with UTI who are prescribed an antibiotic for
<10-day duration
•
Proportion of encounters meeting inclusion who receive empiric cephalexin (oral) or cefazolin (IV)
Process:
•
Frequency of use of new antibiotic prescription folders with recommended medication, dose, and duration
•
Frequency of use of the new UTI order sets (UCC/ED and Inpatient)
Balancing:
•
Return visits to UCC, ED, or inpatient within 14 days

Potential Cost Implications

The following potential improvements may reduce costs and resource utilization for healthcare facilities and reduce
healthcare costs and non-monetary costs (e.g., missed school/work, loss of wages, stress) for patients and families.
•
Decreased risk of overdiagnosis
•
Decreased risk of overtreatment
•
Decreased treatment duration
•
Decreased unwarranted variation in care
•
Decreased risk of antimicrobial resistance

Potential Organizational Barriers and Facilitators
Barriers
•
Variability of acceptable level of risk among providers
•
Challenges with follow-up faced by some families

Facilitators
•
Collaborative engagement across care continuum settings during CPG development
•
High rate of use of CPG
•
Standardized order set for Urgent Care Clinic, Emergency Department, and Hospital Medicine

Power Plans
• Emergency Department/Urgent Care (see Appendix B)
• Inpatient (see Appendix C)
Guideline Preparation

This guideline was prepared by the Evidence Based Practice (EBP) Department in collaboration with content experts at
Children’s Mercy Kansas City. The development of this guideline supports the Service and Performance Excellence
initiative to promote care standardization that builds a culture of quality and safety that is evidenced by measured
outcomes.

Implementation & Follow-up

Once approved, the guideline was presented to appropriate care teams and implemented. Care measurements will be
assessed and shared quarterly with appropriate care teams to determine if changes need to occur.

UTI CPG Committee Members and Representation
•
•
•
•
•
•
•
•

Adrienne DePorre, MD | Hospital Medicine | Committee Chair
Rana El Feghaly, MD, MSCI | Infectious Diseases | Committee Member
Allison Hadley, MD | Emergency Medicine | Committee Member
Amanda Nedved, MD | Urgent Care | Committee Member
Amol Purandare, MD | Infectious Diseases | Committee Member
Christine Scoby, DO | Hospital Medicine | Committee Member
Donna Wyly, MSN, RN, APRN, CPNP-AC, PPCNP-BC, ONC | Urgent Care | Committee Member
Joel Koenig, MD | Urology | Ad hoc Committee Member

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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MIT
•
•
•
EBP

•
•

Committee Members
Amber Lanning | Provider Clinical Informatics
Tracy Taylor | Medical Informatics
George Abraham, MD | Medical Informatics
Committee Members
Kathleen Berg, MD, FAAP | Evidence Based Practice & Hospital Medicine
Jacqueline Bartlett, PhD, RN | Evidence Based Practice

Guideline Development Funding

The development of this guideline was underwritten by the following departments/division: EBP, Urgent Care,
Infectious Diseases, Emergency Medicine, Hospital Medicine and Urology (Surgery).

Conflict of Interest

If a conflict of interest was identified, the conflict was disclosed and the committee member was excluded from
the formulation of a specific recommendation related to the area of conflict. The committee member was allowed
to participate in all other guideline development aspects.

Approval Process

This guideline was reviewed, by an internal and external subject matter expert using the AGREE II instrument
(see Appendix D). The guideline was approved by the UTI CPG Committee, content expert departments/divisions,
and the EBP Department; after which it was approved by the Medical Executive Committee. Guidelines are
reviewed and updated as necessary every 3 years within the EBP Department at CMKC. Content expert
committees will be involved with every review and update.

Approval Obtained

Department/Unit
Hospital Medicine
Emergency Medicine
Urgent Care
Infectious Diseases
Medical Executive Committee

Date Approved
March 2, 2022
June 1, 2022
May 25, 2022
May 19, 2022
May 4, 2022

Version History
Date
09/2011
12/2016
03/2022

Comments
Version one: Utilized AAP UTI guideline
Version two: Utilized AAP Reaffirmation UTI guideline
Version three: Updated all documents using National Institute for Health and Care Excellence
(NICE) (2018) and Subcommittee On Urinary Tract Infection (2016) as foundational
guidelines.

Disclaimer

When evidence is lacking or inconclusive, options in care are provided in the guideline and the power plans that
accompany the guideline.
These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in
determining what is in the best interests of the patient based on the circumstances existing at the time.
It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly,
these guidelines should guide care with the understanding that departures from them may be required at times.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Appendix A: Specific Care Question Measuring the Positive Predictive Value (PPV) for leukocyte esterase (LE) or nitrites (alone or in
combination) to diagnose a UTI
Specific Care Question
In patients > 2 months of age with signs or symptoms of a urinary tract infection (UTI), what is the Positive Predictive Value (PPV) for leukocyte
esterase (LE) or nitrites (alone or in combination) to diagnose a UTI compared to the gold standard of a positive urine culture?
Recommendations from the UTI Clinical Practice Guideline (CPG) Committee
•
A conditional recommendation is made for obtaining a urine culture and treating empirically for a UTI if nitrites are positive, based on the GRADE
Summary of Findings Tablea (see page 9). The recommendation is based on a very low level of evidence (see Summary by Outcome for
substantiation of recommendations). The overall PPV for nitrites to diagnose a UTI was 84% with a negative predictive value (NPV) of 89%.
•
A strong recommendation is made for obtaining a urine culture and treating empirically for UTI if nitrites and LE are positive, based on the GRADE
Summary of Findings Tablea (see page 10). The recommendation is based on a moderate level of evidence (see Summary by Outcome for
substantiation of recommendations). The overall PPV for LE and nitrites to diagnose a UTI was 93% with a NPV of 94%.
•
No literature was found that tested the use of LE alone to accurately identify the need to obtain a urine culture and treat empirically for a UTI within
the last five years.
Literature Summary
Background
UTIs have been identified as one of the most common bacterial infections in childhood (Korbel et al., 2017; Shaikh et al., 2008). Historically clinicians had
tested a urine specimen with a reagent strip that included LE, nitrites, blood, and protein (Downs, 1999). The prevalence of a UTI in febrile infants (greater
than 3 months of age) through adolescence ranges from 6.6% to 7.8% (Shaikh et al., 2008). UTIs are difficult to diagnose in the non-verbal child as the
clinical presentation can be nonspecific (Doern & Richardson, 2016). The gold standard for diagnosing UTI is a positive urine culture (usually >50,000 CFU
of a single uropathogen from a specimen obtained by catheterization, though >10,000 CFU may be appropriate in some clinical scenarios).
Understanding the need to balance testing costs while being antimicrobial stewards, the UTI CPG Committee chose to ascertain if the PPV of LE and/or
nitrites could assist care providers in determining which patients should undergo urine culture and receive empiric antimicrobial therapy, thereby reducing
unneeded lab testing while still identifying UTIs. This review will summarize identified literature to answer the question posed.
Study characteristics.
The search for suitable studies was completed on September 13, 2021. Rana El Feghaly, MD, MSCI and Adrienne DePorre, MD reviewed the 35 titles and/or
abstracts found in the search and identifiedb eight single studies believed to answer the question. After an in-depth review of the single studiesc, six studies
answered the question.
Question Answered. Of the included studies, two (Alghounaim et al., 2021; Liang et al., 2021) were retrospective chart reviews, one (Nadeem et
al., 2021) was a cross-sectional study, one (Prah et al., 2019) employed prospective random sampling and one (Kim et al., 2018) used case control
methodology (see Figure 1). Six of the seven studies enrolled only pediatric patients (Alghounaim et al., 2021; Chaudhari et al., 2017; Kim et al.,
2018; Liang et al., 2021; Lo et al., 2018; Nadeem et al., 2021) while Prah et al. (2019) included adults and children with UTIs in their study (mean
age = 36 years). Four studies (Alghounaim et al., 2021; Kim et al., 2018; Liang et al., 2021; Prah et al., 2019) measured the PPV of nitrites to
diagnose UTIs. Three studies (Alghounaim et al., 2021; Chaudhari et al., 2017; Nadeem et al., 2021) measured the PPV of LE and nitrites to
diagnose UTIs. No studies were identified that measured the PPV of LEs to diagnose UTIs. Of the six studies analyzed, three studies (Alghounaim et
al., 2021; Kim et al., 2018; Prah et al., 2019) had a prevalence significantly higher (51%, 56%, and 30%, respectively) than the reported
prevalence established by Shaikh et al. (2008) which ranged from 6.6% to 7.8%.
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

12
Summary by Outcome
Data Summary by Outcome (rationale for evidence certainty ratinga provided for each outcome)
PPV of Nitrites
Four studies (Alghounaim et al., 2021; Kim et al., 2018; Liang et al., 2021; 3129-Prah et al., 2019) measured the PPV of nitrites to identify a UTI (n =
2610). The overall PPV for nitrites to diagnose a UTI was 84% with a NPV of 89%. It is important to note that as the prevalence of UTI decreases the PPV
decreases as there are more false positives for every true positive (Trevethan, 2017). Additionally, the NPV increases because there are more true
negatives for every false negative (Trevethan, 2017). The prevalence of UTI for the four included studies was 13%. However, based on Shaikh et al. (2008)
published prevalence of 7%, the use of Nitrites would result in 40 to 55 false negatives per 1000 patients (see Table 1). The sensitivity and specificity for
positive nitrites to identify UTI were 84% and 89%, respectively. See the Summary Receiver Operating Curve (SROC), Figure 3, for this outcome.
Certainty of the Evidence for Nitrites to Diagnosis a UTI. The certainty of the body of evidence was very low. The body of evidence was
assessed to not have any imprecision concerns. However, the evidence did have serious risk of bias, serious indirectness, and serious inconsistency
issues. Risk of bias was serious as four studies were judged to be high risk for patient selection and the reviewers were unable to ascertain if the
flow and timing affected the results due to the exclusion of some patients. Indirectness was judged to be serious as three (Alghounaim et al., 2021;
Kim et al., 2018; Prah et al., 2019) of the studies reported higher UTI prevalence (30%, 51%, 56%) than the range of 6.6% to 7.8% reported in an
epidemiologic study (Shaikh et al., 2008). Inconsistency was judged to be serious as the CIs for sensitivity did not overlap (see Figure 5).
PPV of LE and Nitrites
Three studies (Alghounaim et al., 2021; Chaudhari et al., 2017; Nadeem et al., 2021) measured the PPV of LE and nitrites to identify a UTI (n = 39,316).
The overall PPV for LE and nitrites to diagnose a UTI was 93% with a NPV of 94%. The prevalence of UTI for the combined studies was 8%. Therefore the
use of LE and Nitrites would result in 52 to 54 false negatives per 1000 patients (see Table 2). The sensitivity and specificity for the use of LE and nitrites
were 33% and 100%, respectively. See the SROC (Figure 4) for this outcome.
Certainty of the Evidence for LE and Nitrites to Diagnose a UTI. The certainty of the body of evidence was moderate. The body of evidence
was assessed to not have serious inconsistency, indirectness, or imprecision. However, the body of evidence was judged to have serious risk of bias
issues. Two (Alghounaim et al., 2021; Chaudhari et al., 2017) of the studies were judged to be high risk for patient selection and the reviewers
were unable to ascertain if the flow and timing affected the results due to the exclusion of some patients. Alghounai et al. (2021) reported the
prevalence of UTIs in their patient population to be 51% which was significantly higher than the reported range (6.6% to 7.8%) in Shaikh et al.
(2008) epidemiologic study. The other two studies (Chaudari, 2017; and Nadeem, 2021) reported a prevalence of 8%. As Alghounai's sample size
was 179 and the combined sample size of the other studies (Chaudari, 2017; and Nadeem, 2021) equaled 39,137, imprecision was not
downgraded.
Identification of Studies
Search Strategy and Results (see Figure 1)
Search Strategy: "Urinary Tract Infections/diagnosis"[Majr] AND ((("Sensitivity and Specificity"[Mesh] OR "Predictive Value of Tests"[Mesh] OR
"Positive Predictive Value") AND ("leukocyte esterase" or nitrite)) OR (("Urinary Tract Infections/microbiology"[Mesh] OR "urine culture") AND
("leukocyte esterase" or nitrite))) AND (child OR children OR infant OR pediatr* OR paediatr* OR adolescence); Filter applied: last five years.
Records identified through database searching n = 30
Additional records identified through other sources n = 5

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Studies Included in this Review
Citation
Alghounaim et al. (2021)
Chaudhari et al. (2017)
Kim et al. (2018)
Liang et al. (2021)
Nadeem et al. (2021)
Prah et al. (2019)

Study Type
Retrospective cohort
Retrospective cohort
Case Control
Retrospective cohort
Cross-sectional
Prospective random sampling

Studies Not Included in this Review with Exclusion Rationale
Citation
Reason for exclusion
Coulthard (2019)
Author recalculated sensitivity and specificity
Lo et al. (2018)
Study population were infants < 3 months of age, the median age (SD) was 1.5 months (0.7)
Methods Used for Appraisal and Synthesis
aThe GRADEpro Guideline Development Tool (GDT) is the tool used to create the Summary of Findings (SOF) table(s) for this analysis. Using the GDT, the author of
this CAT rates the certainty of the evidence based on four factors: within-study risk of bias, consistency among studies, directness of evidence, and
precision of effect estimates. Each factor is subjectively judged against the author’s confidence of the estimated treatment effect. Confidence is
assessed as not serious, serious or very serious. If the attribute of serious or very serious is assessed, the author will provide an explanation.
bRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
cReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
dThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
References to Appraisal and Synthesis Methods
aGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available
from gradepro.org.
bOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
cHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
dMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Question Originator
UTI CPG Committee
Medical Librarian Responsible for the Search Strategy
K. Swaggart, MLIS, AHIP
EBP Team or EBP Scholar’s Responsible for Analyzing the Literature
J. A. Bartlett, PhD, RN
J. Dusin, MS, RD, LD, CPHQ
A. Melanson, OTD, OTR/L
EBP Medical Director Responsible for Reviewing the Literature
K. Berg, MD, FAAP
T. Glenski, MD, MSHA, FASA
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
J. A. Bartlett, PhD, RN
Acronyms Used in this Document
Acronym
Explanation
CAT
Critically Appraised Topic
CFU
Colony forming units
EBP
Evidence Based Practice
ED
Emergency Department
LE
Leukocyte esterase
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
UTI
Urinary Tract Infection
Statistical Acronyms Used in this Document
Statistical Acronym
Explanation
CI
Confidence Interval
n
Number of cases in a subsample
N
Total number in sample
NPV
Negative Predictive Value
PPV
Positive Predictive Value
RCT
Randomized controlled trial
SR
Systematic Review
SROC
Summary Receiver Operating Curve

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)d

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Figure 2
Summary Risk of Bias and Applicability Concerns

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Sensitivity (true positive rate)

Figure 3
SROC for Nitrites (+) Data

1-Specificity (false positive rate)
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Sensitivity (true positive rate)

Figure 4
SROC for LE (+) and Nitrites (+) Data

Alghounai 2021
Chaudari 2017
Nadeem 2021

1-Specificity (false positive rate)

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 1.
Summary of Findings Table: Should Nitrite (+) be used to diagnose UTI in pts > 2 months of age to adolescence?

Outcome

True positives
(patients with UTI)
False negatives
(patients incorrectly
classified as not
having UTI)
True negatives
(patients without UTI)
False positives
(patients incorrectly
classified as having
UTI)

№ of
studies
(№ of
patients)

Factors that may decrease
Certainty of Evidence (CoE)
Study design

Risk of
bias

4 studies cohort & case394
control type
patients studies

seriousa

4 studies cohort & case2216
control type
patients studies

seriousa

Indirect- Inconsisness
tency
not
serious

not
serious

seriousb

not
serious

Imprecision
seriousc

seriousc

Effect per 1,000 patients tested
Publication
bias
none

none

pre-test
probability
of 7%

pre-test
probability
of 15%

pre-test
probability
of 30%

15 to 30

32 to 65

63 to 129

40 to 55

85 to 118

171 to 237

911 to 930 833 to 850 686 to 700
0 to 19

0 to 17

0 to 14

Test
accuracy
CoE

⨁◯◯◯
Very low

⨁⨁◯◯
Low

Explanations
a. Pt selection from four studies were identified to be high risk. Unclear risk was attributed to the characteristic of flow and timing.
b. Sensitivity data was identified to be inconsistent among the four studies.
c. Three of the five studies reported a higher prevalence value (30%, 51%, 56%) than reported in an epidemiologic study (6.6% to 7.8%).

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Table 2.
Summary of Findings Table: Should LE (+) and Nitrite (+) be used to diagnose UTI in pts > 2 months of age to adolescence?

Outcome

True positives
(patients with UTI)
False negatives
(patients incorrectly
classified as not
having UTI)
True negatives
(patients without UTI)
False positives
(patients incorrectly
classified as having
UTI)

№ of
studies
(№ of
patients)

Factors that may decrease
Certainty of Evidence (CoE)
Study design

Risk of
bias

3 studies cross-sectional
3250
(cohort type
patients accuracy study)

seriousa

3 studies cross-sectional
36066
(cohort type
patients accuracy study)

seriousa

Indirectness

Inconsistency

not
serious

not
serious

not
serious

not
serious

Imprecision
not
seriousb

not
seriousb

Effect per 1,000 patients tested

Test
accuracy
pre-test
pre-test
pre-test
Publication
CoE
probability probability probability
bias
of 8%
of 30%
of 50%
none

none

26 to 28

99 to 105

165 to
175

52 to 54

195 to
201

325 to
335

911 to
920

693 to
700

495 to
500

0 to 9

0 to 7

0 to 5

⨁⨁⨁◯
Moderate

⨁⨁⨁◯
Moderate

Explanations
a. Two of the three studies were judged to have a high risk of bias. Alghounai (2021) sample size was n = 179, while the other (Chaudari, 2017) had a
sample size of n = 14967
b. The prevalence of UTI in Alghounai (2021) was 51% which was significally higher than than the reported range (6.6% to 7.8%) in epidemiologic studies.
However, the other two studies (Chaudari, 2017; and Nadeem, 2021) reported a UTI prevalence of 8%. As Alghounai's sample size was 179 and the
combined sample of the other studies (Chaudari, 2017; and Nadeem, 2021) equaled 39,137, imprecision was not downgraded.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Meta-analyses
Figure 5
Nitrites (+) for All Specimens (Combined Catheterized and Clean Catch)

Figure 6
LE (+) and Nitrites (+) for All Specimens (Combined Catheterized and Clean Catch)

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Characteristics of Diagnostic Studies
Alghounaim et al. (2021)
Patient Selection
A. Risk of Bias
Patient Sampling

Methods: Retrospective Chart Review
Number Enrolled: N = 183
Age Median (IQR): 4.2 years (1.1-7.5)
Gender, Male (%): n = 32 (17.4)
•
292 patients were discharged from Emergency Department (ED) with diagnosis of
UTI
Subjects excluded from study with rationale n = 110 patients based in criteria
•
26 were admitted
•
25 urine culture results were not available (either not ordered [n = 10] or done
elsewhere [n = 15])
•
23 had underlying genitourinary tract abnormalities
•
Two were on UTI prophylaxis
•
Six were transferred to another institution
•
Three were duplicate
•
Six were younger than 12 weeks
•
Seven had conditional antibiotic prescription
•
12 had urine cultures done on therapeutic antibiotics
Race/Ethnicity: not disclosed

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

High risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

23
B. Concerns regarding applicability
Patient characteristics and setting

Setting: Single center, at the Hospital of Sick Children (Toronto, Ontario, Canada)
Timeframe: October to December 2016.
Inclusion:
•
Patients 12 weeks to younger than 18 years
•
Discharged from the ED with the diagnosis of UTI.
Exclusion:
•
Younger than 12 weeks
•
Underlying genitourinary tract abnormalities
•
Admitted or transferred to another center
•
Receiving antibiotics on presentation
•
Urine testing done in another laboratory
•
Received a conditional prescription to be filled if the urine culture was positive
•
Duplicate occurrences (>1 ED visit within the same illness period)

Prevalence (calculated by review author):
•
All Specimens: 51.4%
•
Catheter Specimens: 71.7%
•
Noncatheter Specimens: 41.2%
Are there concerns that the included patients and setting do
not match the review question?

High concern

Index test
Index tests

•
•

Leukoctye Esterase (LE), sensitivity 5–15 white blood cells (WBC)/high power field
o The semi-quantitative results of LE were trace, small (+1), moderate (+2), and large (+3) that corresponded to 15, 75,
125, and 500 WBC/high power field, respectively
Urinary Nitrites, sensitivity 13–22 umol/L Clinitek Status (Siemens Healthcare, Munich, Germany)

All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Yes

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Low concern

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Reference Standard
Target condition and •
reference standard(s) •
•

Confirmed UTI was defined as pyuria and the presence of more than 50,000 CFU/mL (>50,106 CFU/L) of 1 or more uropathogen
In addition, presence of more than 50,000 CFU/mL of a uropathogen along with less than 50,000 CFU/mL of nonuropathogen was
considered significant growth
Unconfirmed UTI included patients with a negative urine culture that was defined as cultures that failed to show bacterial growth
after 24 hours, had growth of less than 50,000 CFU/mL, or had significant but mixed growth of more than 1 organism other than
a typical uropathogen. In addition, growth of a uropathogen and a nonuropathogen, both greater than 50,000 CFU/mL, was
considered to result from contamination

Is the reference standards likely to correctly classify the target condition?

Yes

Were the reference standard results interpreted without knowledge of the results of the index tests?

Yes

Could the reference standard, its conduct, or its interpretation have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

Test done at the same time. Urine culture had to wait on growth.
•
292 patients were discharged from ED with diagnosis of UTI, the study excluded 110 of these patients (see exclusion
criteria)
•
25 urine culture results were not available (either not ordered [n = 10] or done elsewhere [n = 15])

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

Unclear risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Chaudhari et al. (2017)
Patient Selection
A. Risk of Bias
Patient Sampling

Method: Retrospective Chart Review
Number enrolled: N = 14,971
Subjects excluded from study with rationale n = 1,654
Age, median (IQR): 1.5 years (0.4, 5.5)
Gender, Male (%): n = 5,988 (40%)
Race/Ethnicity:
•
white= 40.5%
•
Hispanic = 16.3%
•
African American = 14.4%
•
Asian American = 4.4%
•
Other = 18.1%
•
Unknown = 6.3%

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

High risk

B. Concerns regarding applicability
Patient characteristics and setting

Setting: Single-center, ED
Timeframe: May 2009 and December 2014
Inclusion:
•
Patients younger than 13 years of age
•
Evaluated for UTI
•
Children who had a urine dipstick or micro-urinalysis and a paired urine culture
Exclusion:
•
Urine culture yielded multiple urogenital organisms
•
Nonpathogenic organisms
•
Urine culture was obtained from a urine bag
•
Indwelling urinary catheter
•
Urine source was missing
•
Specific gravity was missing
Prevalence (reported by authors): 7.7%

Are there concerns that the included patients and setting do
not match the review question?

Low concern

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Index test
Index tests

•

Leukocyte Esterase (trace was considered positive) and Nitrites via urine dip stick and categorized by specific gravity

All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Low concern

Reference Standard
Target condition and
reference standard(s)

•
•

For urine specimens obtained by urethral catheterization, positive urine culture was defined by a single urinary pathogen
greater than or equal to 50,000 CFU/mL.
For urine specimens obtained by standard midstream “clean catch,” a positive urine culture for male patients was defined as
having a single urinary pathogen greater than or equal to 50,000 CFU/mL; for female patients, greater than or equal to
100,000 CFU/mL.

Is the reference standards likely to correctly classify the target condition?

Yes

Were the reference standard results interpreted without knowledge of the results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

•
•

Test done at the same time. Urine culture had to wait on growth.
Patients that did not get the reference standard were excluded from the study.

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

Unclear risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Notes

At the study institution, if a dipstick testing result is negative, microscopic urinalysis is not routinely performed. If the patient had a
paired dipstick and urine culture without a microscopic urinalysis, a negative dipstick result was considered equivalent to a negative
microscopic urinalysis result.

Kim et al. (2018)
Patient Selection
A. Risk of Bias
Patient Sampling

Method: Case-control
Number enrolled: N = 79
Age, mean (SD):
•
Case group: 6.30 years (4.77)
•
Control group: 6.71 years (2.74)
Gender, Male (%):
•
Case group: n = 28 (63.6%)
•
Control group: n = 19 (54.3%)
Race/Ethnicity: not disclosed

Was a consecutive or random sample of patients enrolled?

Unclear

Was a case-control design avoided?

No

Did the study avoid inappropriate exclusions?

Yes

Could the selection of patients have introduced bias?

High risk

B. Concerns regarding applicability
Patient characteristics and setting

Setting: Inpatients at the Catholic University of Korea, Bucheon St. Mary's Hospital
Timeframe: March 2013 through January 2015
Inclusion criteria:
•
Case group: Febrile children with a positive urine culture, obtained from a
catheterized specimen, which had pure growth of 100,000 CFU/mL, n = 44
•
Control group: Febrile children with a negative urine culture (how the specimen
was obtained was not reported by the authors), n = 35
Exclusion criteria:
•
Febrile children administered antibiotics before visiting the hospital were excluded
Prevalence (calculated by reviewer): 55.7%

Are there concerns that the included patients and setting do
not match the review question?

Low concern

Index test
Index tests

•
•

YKL-40 (inflammatory marker) levels were obtained upon routine urine collection for culture
Samples were centrifuged at 4°C for 15 minutes at 3,000xg within 30 minutes of collection and stored at -80°C until final
analyses. Samples were tested in duplicate and mean values were presented.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Yes

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

High concern

Reference Standard
Target condition and
reference standard(s)

•

Febrile children with positive urine culture results showing pure growth of 100,000 CFU/mL

Is the reference standards likely to correctly classify the target condition?

Yes

Were the reference standard results interpreted without knowledge of the results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

•
•

Tests done at the same time.
Urine culture had to wait on growth.

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

Unclear risk

Notes

Urine nitrites were only reported in the pts that had a (+) urine culture.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Liang et al. (2021)
Patient Selection
A. Risk of Bias
Patient Sampling

Method: Retrospective Chart Review
Number Enrolled: N = 2144
Subjects excluded from study with rationale: n = 712
•
Non-ED testing, n = 555
•
No matched urinalysis, n = 157
•
Contaminants or asymptomatic or insignificant bacteriuria, n = 141
Age, median (IQR): 1.5 years (0.4, 5.5)
Gender, Male (%): n = 1029 (48%)
Race/Ethnicity (calculated by review author):
•
African American = 85%
•
Hispanic = 6%
•
Asian American = 2%
•
white = 1%
•
Other = 6%

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced bias?

High risk

B. Concerns regarding applicability
Patient characteristics and setting

Setting: Single-center ED, Brooklyn, New York
Timeframe: December 2011 to December 2019.
Inclusion:
•
Children < 2 years of age
•
Urinalysis and urine culture sent
Exclusion:
•
Urine culture was sent without a urinalysis in the same visit
•
Urine testing was not sent from the pediatric ED
Prevalence (reported by author): 9.2%

Are there concerns that the included patients and setting do
not match the review question?

Low concern

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Index test
Index tests

Leukocyte esterase
•
LE were reported by the hospital laboratory as negative, trace, 1+, 2+, and 3+
•
Positive was considered any level
Nitrites
•
Nitrites were measured as positive or negative

All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Low concern

Reference Standard
Target condition and
reference standard(s)

•

UTI was defined per the American Academy of Pediatrics (AAP) guidelines, which require evidence of pyuria or bacteriuria on
urinalysis and >50 000 colony-forming units per mL of a pathogenic bacteria in urine culture from a sterilely obtained
sample.

Is the reference standards likely to correctly classify the target condition?

Yes

Were the reference standard results interpreted without knowledge of the results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

•
•

Tests done at the same time. Urine culture had to wait on growth.
Patients that did not get the reference standard were excluded from the study

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

No

Could the patient flow have introduced bias?

Unclear risk

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Notes

•
•

The providers’ clinical reasoning to send urine was not used as selection criteria to include the widest range of patient
presentations.
Urine collection method not reported.

Nadeem et al. (2021)
Patient Selection
A. Risk of Bias
Patient Sampling

Method: Retrospective cross-sectional study
Number Enrolled: N = 24,171
Participants prior to inclusion/exclusion criteria screening: N = 30,462
Subjects excluded from study with rationale: n = 6,291
Age, median (IQR): 7.3 months (2.5–12.9 months)
Gender, Male (%): 9955 (41.2)
Race/Ethnicity:
•
Hispanic = 54.5%
•
white = 21.1%
•
African American = 17.5%
•
Asian American = 2%
•
Other = 3.1%
•
Unknown = 1.8%

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Yes

Could the selection of patients have introduced bias?

Low risk

B. Concerns regarding applicability
Patient characteristics and setting

Setting: ED of a quaternary children’s hospital in Texas
Timeframe: between January 2012 and December 2017
Inclusion criteria:
•
Children < 24 months of age with suspected UTI
•
Paired urinalysis and urine culture obtained
Exclusion criteria:
•
Patients with >1 ED visit, data from second and subsequent visits were excluded
•
Patients with unknown urine collection source, indwelling catheter, bag urine,
missing urinalysis results, urine culture growing mixed or multiple organisms or
normal genital flora, or missing colony counts
Prevalence (calculated by reviewer): 8.3%

Are there concerns that the included patients and setting do
not match the review question?

Low concern

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Index test
Index tests

Identification of WBCs per high-power field cutoff for microscopic pyuria at three urine specific gravity groups:
•
low <1.011
•
moderate 1.011–1.020
•
high>1.020
in predicting a positive urine culture result

All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Yes

If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the index test have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Low concern

Reference Standard
Target condition and
reference standard(s)

•
•
•

•

Transurethral in-and-out catheterization specimens with growth of >50,000 CFU/mL of a single uropathogen were defined as
positive.
Standard midstream specimens were positive if >100,000 CFU/mL of a single uropathogen grew in culture.
For this study, pathogenic urogenital organisms included
o Escherichia coli,
o Proteus species,
o Klebsiella species,
o Serratia marcescens,
o Citrobacter species,
o Enterobacter species,
o Pseudomonas species,
o Enterococcus species,
o Streptococcus agalactiae, and
o Staphylococcus saprophyticus.
Urine cultures with growth of multiple organisms or urogenital flora were interpreted as contaminated specimens and were
excluded from the study analysis.

Is the reference standards likely to correctly classify the target condition?

Yes

Were the reference standard results interpreted without knowledge of the results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Flow and Timing
A. Risk of Bias
Flow and timing

Tests done at the same time. Urine culture had to wait on growth.

Was there an appropriate interval between index test and reference standard?

Yes

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

Yes

Could the patient flow have introduced bias?

Low risk

Prah et al. (2019)
Patient Selection
A. Risk of Bias
Patient Sampling

Methods: Prospective Random Sampling
Number Enrolled: N = 213
•
UTI patients: n = 64
Age, mean (Range):
•
UTI patients 36.62±17.4 years (9-73 years)
•
non-UTI patients age not reported
Gender, Male (%):
•
UTI patients: n = 16 (25%)
Race/Ethnicity: not disclosed

Was a consecutive or random sample of patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?

Yes

Could the selection of patients have introduced bias?

Low risk

B. Concerns regarding applicability
Patient characteristics and setting

Setting: Single-center Outpatient Clinics, University of Cape Coast Hospital, Ghana
Timeframe: July 2017 – December 2017
Inclusion:
•
Suspected cases of UTI for urinalysis
Exclusion:
•
Urinary obstruction
•
Urinary retention caused by neurological disease
•
Immunosuppression
•
Pregnancy
•
Presence of foreign bodies such as calculi, indwelling catheters or other drainage
devices
•
If a patient had taken antibiotics within two weeks prior to the study.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Prevalence (reported by authors): 30.0%
Are there concerns that the included patients and setting do
not match the review question?

Low concern

Index test
Index tests

Nitrites test
Leukocyte esterase test
Presence of urinary pus cells ≥ 5 per HPF
•
Dipstick urinalysis was done using Combur 10-Test M strips with reagent pads

All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear

If a threshold was used, was it pre-specified?

No

Could the conduct or interpretation of the index test have introduced bias?

Unclear risk

B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Low concern

Reference Standard
Target condition and Urine Culture
reference standard(s)
•
A specimen was considered positive for UTI if a single organism (pure colonies) was cultured at a concentration of ≥105
CFU/ml.
•
In instances of mixed bacterial growth, the procedure was repeated with fresh samples of patients. These were done to rule
out possible contamination.
A. Risk of Bias
Is the reference standards likely to correctly classify the target condition?

Yes

Were the reference standard results interpreted without knowledge of the results of the index tests?

Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question?

Unclear concern

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Flow and Timing
A. Risk of Bias
Target condition and
reference standard(s)

•

Unclear if tests are done at the same time

Was there an appropriate interval between index test and reference standard?

Unclear

Did all patients receive the same reference standard?

Yes

Were all patients included in the analysis?

Yes

Could the patient flow have introduced bias?

Low risk

Notes

•

Patients were asked to provide a clean catch midstream urine in a sterile screw capped universal container

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved
in providing health care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at
the time. It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Appendix B: Emergency Department/Urgent Care Powerplan

Pyelonephritis or Unknown Therapy subphase:

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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EDP Cystitis Therapy subphase:

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Appendix C: Inpatient Powerplans

Pyelonephritis or Unknown Therapy subphase:

Cystitis Therapy subphase:

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Appendix D: AGREE II Assessment for Children’s Mercy Hospitals’ UTI CPG
AGREE IIa Summary for this Clinical Practice Guideline*
Domain

Percent Agreement

Scope and purpose

92%

Stakeholder involvement

69%

Rigor of development

84%

Clarity and presentation

89%

Applicability

96%

Editorial independence
96%
Reviewer’s recommendation for
Yes
guideline use
*Note: This assessment reflects the views obtained from one external clinician and one internal clinician.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.

